| 763898 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
580 Glutamine blockade in combination with immune checkpoint blockade remodels the myeloid landscape in mouse models of soft tissue sarcomas |
2021-11-01 |
10.1136/jitc-2021-sitc2021.580 |
Suru Aditya, Islam Marwa, Tam Ada, Gross John, Llosa Nicolas |
| 763897 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.408 |
Naing Aung, Kim Richard, Barve Minal, Johnson Melissa, Lee Byung Ha, Ferrando-Martinez Sara, Pant Shubham, Wolff Robert, Haymaker Cara, Chaney Marya, Kim Dae Won, Fan Jean, Le NgocDiep, Mamdani Hirva |
| 763896 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
695 Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.695 |
Mahmoodi Amir, Srinivasan Sangeetha, Zakharian Michael, Yee Nathan, McFarland Jesse, Oneto Jose Mejia |
| 763895 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
113 CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition |
2021-11-01 |
10.1136/jitc-2021-sitc2021.113 |
Guo Chao, Fan Yanying, Aronov Alexander, Buren Luxuan, Xie Ming-Hong, Chan Ivan, Lazetic Sasha, Trager James |
| 763894 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
249 Characterization of unresectable and/or metastatic solid tumors patients treated with systemic anticancer therapy in first-line settings: a pan-tumor community-oncology based study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.249 |
Wu Elise, Sura Sneha, Spira Alexander |
| 763893 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.493 |
Johnson Melissa, Lopez Juanita, LoRusso Patricia, Bauman Jessica, Haggstrom Daniel, Lagkadinou Eleni, Bajaj Gaurav, Türeci Özlem, Adams Homer, Şahin Uğur, Fu Yali, Ahmadi Tahamtan, Rohrberg Kristoffer |
| 763892 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
138 Synthetic re-direction of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.138 |
Peralta Eigen, Carron Emily, Chu Hui-Yi, Loter Lorraine, Navarrete Natalie, Tam Arvin, Mehta Amit, Lu Dan, Chu Philip, Lyon Kenyon, Pan Yijia, Pribadi Mochtar, Witty Alec, Lee Tom, Valamehr Bob |
| 763891 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b |
2021-11-01 |
10.1136/jitc-2021-sitc2021.706 |
Berezhnoy Alexey, Wang Hsin, Cai Na, Assi Hikmat, Lapuyade Nicole, Paidhungat Madan, Wong Kenneth, Krimm Michael, Dunn Robert, Daniel Dylan, Belvin Marcia, Scolan Erwan Le |
| 763890 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
581 Multi-dimensional Synergy of Combinations (MuSYC) Algorithm Optimizes Combinatorial STING and TLR Adjuvant Cancer Vaccines |
2021-11-01 |
10.1136/jitc-2021-sitc2021.581 |
Taylor David, Korrer Michael |
| 763889 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90% |
2021-11-01 |
10.1136/jitc-2021-sitc2021.312 |
Ricciuti Biagio, Alessi Joao Victor, Alden Stephanie, Lamberti Giuseppe, Vaz Victor, Barrichello Adriana, Sholl Lynette, Awad Mark |
